A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Li, Xiuxiu ^a   Xu, Xue ^a   Wang, Jinan ^a   Yu, Hua ^a   Wang, Xia ^a   Yang, Hongjun ^b   Xu, Haiyu ^b   Tang, Shihuan ^b   Li, Yan ^c   Yang, Ling ^d   Huang, Luqi ^b   Wang, Yonghua ^a   Yang, Shengli ^d  

^a NORTHWEST A F UNIVERSITY   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^d DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SALVIA MILTIORRHIZA EXTRACT;

ARTICLE; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; COMPUTER MODEL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; HUMAN; MOLECULAR DYNAMICS; PANAX NOTOGINSENG; PROTEIN TARGETING; SALVIA MILTIORRHIZA; TRADITIONAL MEDICINE;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PHARMACOGENETICS; PHENANTHROLINES; SALVIA MILTIORRHIZA; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; THERMODYNAMICS;

EID: 84866040675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043918     Document Type: Article

References (122)

1. World Health Organization website. Available: http://www.who.int/topics/cardiovascular_diseases/en/. Accessed 2012 June 20.
2. Xu J, Wu H, (2009) Chinese herbal medicine and acupuncture for the treatment of cardiovascular disease. J Geriatr Cardiol 6: 56-61.
3. State Pharmacopoeia Commission of the PRC (2005) Pharmacopoeia of People's Republic of China, 2005. Beijing: Chemical Industry Press.
4. Ding N, (2002) Development and clinical application of compound danshen dripping pills. Chin Tradit Herb Drugs 33: 1147-1148.
5. Wu YJ, Hong CY, Lin SJ, Wu P, Shiao MS, (1998) Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza. Thromb Vasc Biol 18: 481-486.
6. Karmin O, Lynn EG, Vazhappilly R, Au-Yeung KKW, Zhu DY, et al. (2001) Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. Life Sci 68: 903-912.
7. Takahashi K, Ouyang X, Komatsu K, Nakamura N, Hattori M, et al. (2002) Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells. Biochem Pharmacol 64: 745-750.
8. Normile D, (2003) The new face of traditional Chinese medicine. Science 299: 188-190.
9. Zhao J, Jiang P, Zhang W, (2010) Molecular networks for the study of TCM Pharmacology. Brief Bioinform 11: 417-430.
10. Hopkins AL, (2007) Network pharmacology. Nat Biotechnol 25: 1110-1111.
11. Barabási AL, (2009) Scale-free networks: a decade and beyond. Science 325: 412-413.
12. Janga SC, Tzakos A, (2009) Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Mol BioSyst 5: 1536-1548.
13. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
14. van der Greef J, (2011) Perspective: All systems go. Nature 480: S87.
15. Wang BQ, (2010) Salvia miltiorrhiza: Chemical and pharmacological review of a medicinal plant. J Med Plants Res 4: 2813-2820.
16. Bao J, Liu G, Cong D, Zhang C, (2006) Research progress of chemical composition about Panax pseudoginseng. Chin Trad Patent Med 28: 246-253.
17. Chen J, Zeng H, Li G, Ouyang S, (2005) Ingredients analysis of Longnaozhang volatile and natural borneol. J Chin Med Mater 28: 781-782.
18. Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ, (1996) Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int 38: 1171-1182.
19. Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, et al. (2007) Tanshinone IIB, a primary active constituent from Salvia miltiorrhza, exhibits neuro-protective activity in experimentally stroked rats. Neurosci Lett 417: 261-265.
20. Wang Y, Deng W, Xue C (1998) Pharmacology and Application of Chinese Medicine. 2nd Ed. Beijing: People's Medical Publishing House.
21. Qiao X, Hou T, Zhang W, Guo SL, Xu X, (2002) A 3D structure database of components from Chinese traditional medicinal herbs. J Chem Inf Comp Sci 42: 481-489.
22. Zhang HX, Li Y, Wang X, Xiao ZT, Wang YH, (2011) Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase Inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Curr Med Chem 18: 4019-4028.
23. Li Y, Wang YH, Yang L, Zhang SW, Liu CH, et al. (2005) Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis. J Mol Struct 733: 111-118.
24. Xu X, Zhang W, Huang C, Li Y, Yu H, et al. (2012) A novel chemometric method for prediction of human oral bioavailability. Int J Mol Sci 13: 6964-6982.
25. Bioinformatics and CADD website. Available: http://modem.ucsd.edu/adme. Accessed 2012 June 20.
26. Liu X, Ouyang S, Yu B, Liu Y, Huang K, et al. (2010) PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 38: W609-W614.
27. Zhu F, Han BC, Kumar P, Liu XH, Ma XH, et al. (2010) Update of TTD: therapeutic target database. Nucleic Acids Res 38: D787-D791.
28. Thorn CF, Klein TE, Altman RB, Pharm G, (2005) The Pharmacogenetics and Pharmacogenomics Knowledge Base. Methods Mol Biol 311: 179-191.
29. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-D906.
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat T, et al. (2000) The protein data bank. Nucleic Acids Res 28: 235-242.
31. Xu X, Li R, Ma M, Wang X, Wang Y, et al. (2012) Multidrug resistance protein P-glycoprotein does not recognize nanoparticle C60: experiment and modeling. Soft Matter 8: 2915-2923.
32. Gasteiger J, Marsili M, (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36: 3219-3228.
33. Medina-Franco JL, López-Vallejo F, Kuck D, Lyko F, (2011) Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol Divers 15: 293-304.
34. Case D, Darden T, Cheatham Iii T, Simmerling C, Wang J, et al. (2008) AMBER 10. University of California, San Francisco 32.
35. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24: 1999-2012.
36. Jakalian A, Jack DB, Bayly CI, (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 23: 1623-1641.
37. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157-1174.
38. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A smooth particle mesh Ewald method. J Chem Phys 103: 8577-8593.
39. Massova I, Kollman PA, (2000) Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discovery Des 18: 113-135.
40. Still WC, Tempczyk A, Hawley RC, Hendrickson T, (1990) Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 112: 6127-6129.
41. McQuarrie D (2000) Statistical Mechanics. Sausalito: CA: University Science Books.
42. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T, (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432.
43. Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M, (2008) Computing topological parameters of biological networks. Bioinformatics 24: 282-284.
44. Scardoni G, Petterlini M, Laudanna C, (2009) Analyzing biological network parameters with CentiScaPe. Bioinformatics 25: 2857-2859.
45. Tian P, (2011) Convergence: Where west meets east. Nature 480: S84-S86.
46. Li J (2011) Illustration of Traditional Chinese Medicine formulations. Wuhan: Wuhan Publishing House.
47. Kong DX, Li XJ, Zhang HY, (2009) Where is the hope for drug discovery? Let history tell the future. Drug Discov Today 14: 115-119.
48. Sucher NJ, (2006) Insights from molecular investigations of traditional Chinese herbal stroke medicines: Implications for neuroprotective epilepsy therapy. Epilepsy Behav 8: 350-362.
49. Wang L, Zhou GB, Liu P, Song JH, Liang Y, et al. (2008) Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105: 4826-4831.
50. Shen YJ (2009) Pharmacology of Traditional Chinese Medicine. Beijing: The People's Medical Publishing House.
51. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, et al. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-2623.
52. Yang L, Liu H, Ma H, Liu Y, Hao D, (2007) Application of systems biology to absorption, distribution, metabolism and excretion in Traditional Chinese Medicine. World Sci Tech-Modern Trad Chin Med 9: 98-104.
53. Pei WJ, Zhao XF, Zhu ZM, Lin CZ, Zhao WM, et al. (2004) Study of the determination and pharmacokinetics of Compound Danshen Dripping Pills in human serum by column switching liquid chromatography electrospray ion trap mass spectrometry. J Chromatogr B 809: 237-242.
54. Liu H, (2008) The application of Salvia miltiorrhiza active ingredients in the research of cardiovascular pharmacology. Modern J Integrated Traditional Chin Western Med 17: 5397-5399.
55. Shi CS, Huang HC, Wu HL, Kuo CH, Chang BI, et al. (2007) Salvianolic acid B modulates hemostasis properties of human umbilical vein endothelial cells. Thromb Res 119: 769-775.
56. Chen YL, Hu CS, Lin FY, Chen YH, Sheu LM, et al. (2006) Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta. J Cell Biochem 98: 618-631.
57. Zhang HS, Wang SQ, (2006) Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-α(TNF-α)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD (P) H oxidase-derived reactive oxygen species. J Mol Cell Cardiol 41: 138-148.
58. Zhang J, He Y, Cui M, Li L, Yu H, et al. (2005) Metabolic studies on the total phenolic acids from the roots of Salvia miltiorrhiza in rats. Biomed Chromatogr 19: 51-59.
59. Xu D, Wang K, Wang Z, Wang C, Hu J, (2005) Primary study on the original problems of danshensu and protocatechuic aldehyde of Salvia miltiorrhiza. Chin J Nat Med 3: 148-150.
60. Wu YT, Chen YF, Hsieh YJ, Jaw I, Shiao MS, et al. (2006) Bioavailability of salvianolic acid B in conscious and freely moving rats. Int J Pharm 326: 25-31.
61. Zhou L, Zuo Z, Chow MSS, (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45: 1345-1359.
62. Xie GX, Qiu YP, Qiu MF, Gao XF, Liu YM, et al. (2007) Analysis of dencichine in Panax notoginseng by gas chromatography-mass spectrometry with ethyl chloroformate derivatization. J Pharmaceut Biomed 43: 920-925.
63. Formica J, Regelson W, (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33: 1061-1080.
64. Leung KW, Wong AST, (2010) Review Pharmacology of ginsenosides: a literature review. Chin Med 5: 20.
65. Odani T, Tanizawa H, Takino Y, (1983) Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. II. The absorption, distribution and excretion of ginsenoside Rg1 in the rat. Chem Pharm Bull 31: 292-298.
66. Karikura M, Miyase T, Tanizawa H, Takino Y, Taniyama T, et al. (1990) Studies on absorption, distribution, excretion and metabolism of ginseng saponins. V, The decomposition products of ginsenoside Rb2 in the large intestine of rats. Chem Pharm Bull 38: 2859-2861.
67. Xu QF, Fang XL, Chen DF, (2003) Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 84: 187-192.
68. Gu Y, Wang GJ, Sun JG, Jia YW, Wang W, et al. (2009) Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem Toxicol 47: 2257-2268.
69. Han M, Fang X, (2006) Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models. Acta Pharmacol Sin 27: 499-505.
70. Xie HT, Wang GJ, Chen M, Jiang X, Li H, et al. (2005) Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells. Biol Pharm Bull 28: 383-386.
71. Hwang YP, Jeong HG, (2010) Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol 242: 18-28.
72. Zhu D, Wu L, Li CR, Wang XW, Ma YJ, et al. (2009) Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. J Cell Biochem 108: 117-124.
73. Leung KW, Pon YL, Wong RNS, Wong AST, (2006) Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and β-catenin/T-cell factor-dependent pathway in human endothelial cells. J Biol Chem 281: 36280-36288.
74. He F, Guo R, Wu SL, Sun M, Li M, (2007) Protective effects of ginsenoside Rb1 on human umbilical vein endothelial cells in vitro. J Cardiovasc Pharmacol 50: 314-320.
75. Chen F, Eckman EA, Eckman CB, (2006) Reductions in levels of the Alzheimer's amyloid ß peptide after oral administration of ginsenosides. FASEB J 20: 1269-1271.
76. Hasegawa H, Sung JH, Benno Y, (1997) Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 63: 436-440.
77. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K, (1998) Drug Metabolism: Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of Ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 50: 1155-1160.
78. Popovich DG, Kitts DD, (2002) Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch Biochem Biophys 406: 1-8.
79. Bae EA, Han MJ, Kim EJ, Kim DH, (2004) Transformation of ginseng saponins to ginsenoside Rh 2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res 27: 61-67.
80. Chen X, Lin Z, Liu A, Ye J, Luo Y, et al. (2010) The orally combined neuroprotective effects of sodium ferulate and borneol against transient global ischaemia in C57 BL/6J mice. J Pharm Pharmacol 62: 915-923.
81. Zhao B, Dong SY, Mi SQ, Wang N, (2002) The influence of borneol to the iNOS of brain microvascular endothelial cells. Chin Pharmacol Bull 18: 590-591.
82. Wu SR, Cheng G, Wang L, Zou MJ, Gui FD, (2003) Effects of borneol on the absorption kinetics of the rifampicin in rat's intestines. J Shenyang Pharm Univ 20: 245-248.
83. Zhou Y, Li W, Chen L, Ma S, Ping L, et al. (2010) Enhancement of intestinal absorption of akebia saponin D by borneol and probenecid in situ and in vitro. EnvironToxicol Phar 29: 229-234.
84. Wang YH, Li Y, Yang SL, Yang L, (2005) An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. J Comput Aided Mol Des 19: 137-147.
85. Wang YH, Li Y, Yang SL, Yang L, (2005) Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 45: 750-757.
86. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722.
87. Chen Y, Wang N, (2004) Effect of borneol on the intercellular tight junction and pinocytosis vesicles in vitro blood-brain barrier model. Chin J Integrated Tradit West Med 24: 632-634.
88. Zheng X, Zhao X, Fang M, Wang S, Wei Y, et al. (2007) Pharmacokinetic effects of Shi herb-Borneol on Jun herb-Salvia Miltiorrhiza. Journal of Xi'an Jiaotong University (Medical Sciences) 28: 171-173.
89. Nabel EG, (2003) Cardiovascular disease. New Engl J Med 349: 60-72.
90. Cases M, Mestres J, (2009) A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov Today 14: 479-485.
91. Kuruvilla FG, Shamji AF, Sternson SM, Hergenrother PJ, Schreiber SL, (2002) Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 416: 653-657.
92. Reddy AS, Pati SP, Kumar PP, Pradeep H, Sastry GN, (2007) Virtual screening in drug discovery-a computational perspective. Curr Protein Pept Sci 8: 329-351.
93. Citterio L, Lanzani C, Manunta P, (2011) Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics 12: 1587-1604.
94. Peitz GJ, Malesker MA, Sojka SG, (2009) Aliskiren-induced QT interval prolongation. South Med J 102: 411-412.
95. Kitano H, (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 5: 202-210.
96. Li XM, Brown LV, (2009) Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 123: 297-306.
97. Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I, (2007) Revisiting the ancient concept of botanical therapeutics. Nat Chem biol 3: 360-366.
98. Lee S, Park K, Kim D, (2009) Building a drug-target network and its applications. Expert Opin Drug Discov 4: 1177-1189.
99. Berger SI, Iyengar R, (2009) Network analyses in systems pharmacology. Bioinformatics 25: 2466-2472.
100. Azuaje FJ, Zhang L, Devaux Y, Wagner DR, (2011) Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs. Scientific Reports 1: 1-10.
101. Özgür A, Vu T, Erkan G, Radev DR, (2008) Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics 24: i277-i285.
102. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M, (2007) The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 3: e59.
103. Jeong H, Mason SP, Barabasi AL, Oltvai ZN, (2001) Lethality and centrality in protein networks. Nature 411: 41-42.
104. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, et al. (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145: 863-874.
105. Dzau V, Braunwald E, (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121: 1244-1263.
106. Mencher S, Wang L, (2005) Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5: 3-13.
107. Shao L, Bo Z, Duo J, Yingying W, Ningbo Z, (2010) Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. BMC Bioinformatics 11: S6.
108. Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M, (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
109. Ferrario CM, Strawn WB, (2006) Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121-128.
110. Smoak KA, Cidlowski JA, (2004) Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 125: 697-706.
111. Barger PM, Kelly DP, (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10: 238-245.
112. Sangkuhl K, Shuldiner AR, Klein TE, Altman RB, (2011) Platelet aggregation pathway. Pharmacogenet Genom 21: 516-521.
113. Wyatt AW, Steinert JR, Mann GE, (2004) Modulation of the L-arginine/nitric oxide signalling pathway in vascular endothelial cells. Biochem Soc Symp 71: 143-156.
114. Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J, (2007) TGF-β signaling in vascular fibrosis. Cardiovasc Res 74: 196-206.
115. Zhou M, Li X, Li X, Xu Y, Yang M, (2009) Effects of Tanshinone IIA on platelets and coagulation in immune vasculitis. Chin J Thromb Haemost 15: 8-12.
116. Lee CH, Olson P, Evans RM, (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144: 2201-2207.
117. Ji XY, Tan B, Zhu YZ, (2000) Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 21: 1089-1094.
118. Zhang M, Li X, Jiu G, Liu Y, (2003) Effect of danshen injection on expression of platelet membrane glycoproteins in patients with type II diabetes mellitus. J Chin Med Mater 26: 738-740.
119. Tian X, Xue W, Ding X, (2005) Application of Danshen injection on early stage of renal transplantation. Chin J Integrated Tradit West Med 25: 404-407.
120. Bao H, Yu H, Wang L, (2002) Study on effect of Salvia injection in treating primary nephrotic syndrome and on endothelin and serum interleukin-2 receptor in children. Chin J Integrated Tradit West Med 22: 28-29.
121. Chang Y, (2009) New application of Compound Danshen Tabuletta. Seek Medical and Ask the Medicine 1: 32.
122. Du D, (2008) The Baiyunshan Compound Danshen Tabulettacan can be used to prevent and cure Alzheimer's Disease. Chin J Inf TCM 9: 44.